HC Wainwright Weighs in on Caribou Biosciences, Inc.’s Q1 2024 Earnings (NASDAQ:CRBU)

Caribou Biosciences, Inc. (NASDAQ:CRBUFree Report) – HC Wainwright lifted their Q1 2024 earnings estimates for Caribou Biosciences in a report issued on Tuesday, March 19th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.39) for the quarter, up from their prior forecast of ($0.42). HC Wainwright currently has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.76) per share. HC Wainwright also issued estimates for Caribou Biosciences’ Q2 2024 earnings at ($0.40) EPS, Q3 2024 earnings at ($0.42) EPS, Q4 2024 earnings at ($0.45) EPS and FY2024 earnings at ($1.66) EPS.

Caribou Biosciences Price Performance

CRBU opened at $5.23 on Thursday. The company’s 50-day moving average is $6.38 and its 200 day moving average is $5.56. Caribou Biosciences has a fifty-two week low of $3.44 and a fifty-two week high of $8.59. The firm has a market capitalization of $472.37 million, a P/E ratio of -3.61 and a beta of 2.59.

Hedge Funds Weigh In On Caribou Biosciences

Several large investors have recently modified their holdings of CRBU. Swiss National Bank increased its stake in shares of Caribou Biosciences by 8.0% in the first quarter. Swiss National Bank now owns 57,000 shares of the company’s stock worth $523,000 after purchasing an additional 4,200 shares in the last quarter. ProShare Advisors LLC lifted its position in Caribou Biosciences by 22.1% during the first quarter. ProShare Advisors LLC now owns 15,766 shares of the company’s stock valued at $145,000 after purchasing an additional 2,856 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Caribou Biosciences by 2,754.9% during the first quarter. JPMorgan Chase & Co. now owns 515,758 shares of the company’s stock valued at $4,735,000 after purchasing an additional 497,692 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Caribou Biosciences by 108.2% during the first quarter. Bank of New York Mellon Corp now owns 141,262 shares of the company’s stock valued at $1,297,000 after purchasing an additional 73,427 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its position in Caribou Biosciences by 311.7% during the first quarter. MetLife Investment Management LLC now owns 31,003 shares of the company’s stock valued at $285,000 after purchasing an additional 23,472 shares during the last quarter. Hedge funds and other institutional investors own 59.16% of the company’s stock.

About Caribou Biosciences

(Get Free Report)

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma.

Read More

Earnings History and Estimates for Caribou Biosciences (NASDAQ:CRBU)

Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.